India Working On 7 More Vaccines

[Anta Assamey]

Union Health Minister Harsh Vardhan has earlier stated that India is developing seven more effective COVID-19 vaccines, besides working on further vaccine development. However, he clarified that the government is not planning to make the vaccines available to the public immediately.

While the vaccines may take time to come into the market, the decision on it is negotiable with the situational demands. Union Health Minister further added that the third phase of vaccination for citizens who are above the age of 50 years and those who are younger but with serious co-morbidities is likely to begin in March.

“Our country is not reliant on only the two vaccines as we are striving hard to create seven more indigenous vaccines. Parallel to that, India is also working on the development of more vaccines, keeping in mind that India is a huge country,” Harsh Vardhan stated. Among these upcoming seven vaccines, three of them are in the trial phase, two are in the pre-clinical stage, one is in phase 1 and another in phase 2. 

So far,  nearly 58 lakh healthcare and frontline workers were given vaccinations against COVID-19 in the country and thus, making India as the third country in the world with the highest doses of vaccination.

[JustChill_Mama]

Annendhuku ra bujjaaa..... manam emayina pelli gani elthunnama

[Assam_Bhayya]

[betapilli]

4 minutes ago, JustChill_Mama said:

Annendhuku ra bujjaaa..... manam emayina pelli gani elthunnama

Good post

[Sachin200]

7 minutes ago, betapilli said:

Good post

Oxford/AstraZeneca jab fails to prevent coronavirus from South African strain: Study

British drugmaker AstraZeneca said on Saturday its vaccine developed with the University of Oxford appeared to offer only limited protection against mild disease caused by the South African variant of COVID-19, based on early data from a trial.

The study from South Africa's University of the Witwatersrand and Oxford University showed the vaccine had significantly reduced efficacy against the South African variant, according to a Financial Times report published earlier in the day.